Suggested Searches

photo of Arvinda Padmanabhan
859-276-0414

Arvinda Padmanabhan, MD

Hematology Oncology
Gender: Male
4.9 of 5 (263 Ratings)
Accepting New Patients
Virtual Visits

Clinical Focus

Brain and Spinal Cord Tumors, Cancerous tumors

Practice Locations

A:
Baptist Health Medical Group Hematology & Oncology
1700 Nicholasville Road, Suite 1100
Lexington, KY 40503
859-276-0414 859-276-3765
B:
Baptist Health Medical Group Hematology & Oncology
3000 Baptist Health Blvd Ste 155
Lexington, KY 40509
859-276-0414 859-276-3765

Education

Medical School

University of Kentucky College of Medicine

Residency

University of South Florida College of Medicine

Fellowship

University of Kentucky Medical Center

Internship

University of Kentucky Internal Medicine Residency

Board Certifications

Hematology

American Board of Internal Medicine

Medical Oncology

American Board of Internal Medicine

Hospital Affiliations

  • Baptist Health Richmond
  • Baptist Health Lexington

Philosophy of Care

Baptist Health Medical Group is a comprehensive, multispecialty network of physicians and advanced practice clinicians. Our providers are committed to providing compassionate, patient-centered care and strive to treat our patients the way we would want to be treated, every time, at every Baptist Health location.

Reviews

Patient Experience Ratings

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Overall Rating
4.9 out of 5 (263 Ratings)
Review Categories
Patient Comments

Research

  • Early Cancer Detection (SIRB-22-0046)

    Adela CAMPERR: cfMeDIP-seq Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse (CAMPERR)

    Trial Details
  • All Advanced Cancers

    An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations

    Trial Details
  • Brain Cancer

    ECOG-ACRIN EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab (Avastin) in Recurrent Glioblastoma

    Trial Details
  • Cancer

    Ascend 2: Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II (DETECT-ASCEND 2)

    Trial Details
  • Malignant Solid Neoplasm (CIRB-23-0049)

    S2205: ice compress: randomized trial of limb cryocompression versus continuous compression versus low cyclic compression for the prevention of taxane-induced peripheral neuropathy.

    Trial Details
  • Non-small cell lung cancer, pancreatic, or colorectal cancer (SIRB-22-0045)

    Cachexia: a phase 2, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of ponsegromab in patients with cancer, cachexia, and elevated concentrations of gdf-15, followed by an optional open-label treatment period (proacc -1)

    Trial Details
  • Recurrent Glioblastoma, Secondary Glioblastoma

    A071702: A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

    Trial Details